Secondary Intelligence™ Demo
Discover how Secondary Intelligence™ can support your compound assessments by predicting off-target activities and potential…
Certara2024 年 5 月 24 日
Quantitative systems pharmacology-based exploration of relevant anti-amyloid therapy challenges in clinical practice
Addressing practical challenges in clinical practice after the recent approvals of amyloid antibodies in Alzheimer's…
Certara2024 年 5 月 22 日
CERTAINTY Europe
GREATER CERTAINTY IN DRUG DEVELOPMENT Certainty by Certara offers exclusive access to Certara experts, industry leaders, and…
Danielle Pillsbury2024 年 5 月 22 日
Clinical Pharmacology & Model-Informed Drug Development Insights for Targeted Radiation Therapies
靶向放射性核素治疗（TRT）通过将细胞毒性辐射选择性作用于肿瘤实现精准治疗。In recent years, oncology drug…
Danielle Pillsbury2024 年 5 月 22 日
Certara Appoints New Chief Human Resources Officer & General Counsel
RADNOR, PA – 2024 年 5 月 21 日 – Certara, Inc. （纳斯达克股票代码：CERT), a global leader in…
Danielle Pillsbury2024 年 5 月 21 日
Accelerating the Progress of Kinase Inhibitors in Oncology
The potential of PBPK modeling in answering key questions around these drugs. Hannah Jones, PhDMasoud…
Certara2024 年 5 月 20 日
Unlocking Efficiency in Formulation Development and Approvals with MIFD & Simcyp Biopharmaceutics [APAC Webinar]
Biopharmaceutical professionals can gain a significant edge in formulation development by attending this free webinar…
Danielle Pillsbury2024 年 5 月 16 日
Reflections on the New FDA Clinical Pharmacology Guidance for Antibody-Drug Conjugates
In recent years, oncology drug developers have invested in antibody-drug conjugates (ADCs). These targeted therapies…
Certara2024 年 5 月 10 日
CERTARA & CLOUDSCIENTIFIC ACCELERATE AI FOR DRUG DEVELOPMENT IN CHINA
Partnership will provide biopharmaceutical companies with advanced tools and solutions needed to expedite research …
Certara2024 年 5 月 10 日
